limertinib

Biomarkers

Sponsors

Industry sponsors leading active biomarker-selected trials of limertinib.

1. Jiangsu Aosaikang Pharmaceutical 3
2. Innovent Biologics 1

Trials

9 of 11 trials shown

1. ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

   Not yet recruiting Phase 3 Jiangsu Aosaikang Pharmaceutical Started 2026Primary completion 2030-12 NCT07897188

   ASKC202ASKC202 placeboosimertinib FDA EUpemetrexedcisplatincarboplatinlimertinib

   The tumor harbors EGFR sensitizing mutation (Ex19Del or L858R).

   EGFR exon 19 deletion / L858REGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive

2. ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

   Recruiting Phase 3 Jiangsu Aosaikang Pharmaceutical Started 2025Primary completion 2027-10 NCT07109531

   limertinibpemetrexedcisplatincarboplatin

   EGFR mutation with MET amplification/Overexpression by a central laboratory;

   EGFR exon 19 deletion / L858RLocally Advanced or Metastatic NSCLC

3. Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases

   Not yet recruiting Phase 2 The First Affiliated Hospital of Guangzhou Medical University Started 2026Primary completion 2027-12 NCT07413952

   limertinib

   … or third-party testing institutions confirming the presence of EGFR classical mutations (19Del \& 21L858R).

   EGFR exon 19 deletion / L858RNSCLC

4. Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

   Not yet recruiting Phase 2 Hunan Province Tumor Hospital Started 2026Primary completion 2027-12 NCT07001995

   limertinibetoposidecarboplatin

   …ologically confirmed non-small cell lung cancer (NSCLC) with a sensitizing EGFR mutation (exon 19 deletion or L858R, with or without concurrent mutations).

   EGFR exon 19 deletion / L858RSmall Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer NSCLC

5. Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

   Not yet recruiting Phase 1/2 Innovent Biologics Started 2026Primary completion 2027-06 NCT07612137

   IBI3005sintilimabbevacizumablimertinibosimertinib FDA EUcarboplatin

   Tumor harboring EGFR-sensitive mutations (Ex19del or L858R, with or without other EGFR mutations) confirmed via histology or cytology speci…

   EGFR exon 19 deletion / L858RSolid Tumor

6. Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

   Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai Started 2026Primary completion 2026-06 NCT07323056

   sacituzumab tirumotecanlimertinib

   Patients with non-small cell lung cancer (NSCLC) with EGFR mutation confirmed by pathology

   EGFR exon 19 deletion / L858REGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable

7. A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

   Not yet recruiting Phase 2 Shanghai Chest Hospital Started 2025Primary completion 2026-12 NCT06982924

   limertinibbevacizumab

   Confirmed EGFR - sensitive mutations (Ex19del, L858R) in tumor histology or cytology or in hematology.

   EGFR exon 19 deletion / L858REGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive

8. A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC

   Not yet recruiting Phase 2 Wen-zhao ZHONG Started 2025Primary completion 2027-12 NCT07038460

   limertinibsintilimabosimertinib FDA EU

   …ollowed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC

   EGFR exon 19 deletion / L858RResectable Non-small Cell Lung Cancer

9. Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

   Recruiting Phase 1 Jiangsu Aosaikang Pharmaceutical Started 2022Primary completion 2026-12 NCT05306132

   ASKC202limertinib

   …ocally advanced or metastatic NSCLC;b)Histologically confirmed EGFR sensitizing mutation (Ex19del or L858R).；c)Disease progression following treatment with a third-generation EGFR TKI, or…

   EGFR exon 19 deletion / L858RAdvanced Solid Tumor

No trials match these filters.